智翔金泰：GR1802注射液青少年季节性过敏性鼻炎适应症获临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its product GR1802 injection for the indication of seasonal allergic rhinitis in adolescents [1] Group 1: Product Development - GR1802 injection is a recombinant fully human anti-IL-4Rα monoclonal antibody developed by the company, targeting IL-4Rα [1] - The product has previously received clinical trial approval for multiple indications, including moderate to severe atopic dermatitis in adults, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis, all of which are currently in Phase III clinical trials [1] - The asthma indication is in Phase II clinical trials, while the indication for atopic dermatitis in children/adolescents is in Phase Ib/II clinical trials [1]